Skip to main content
RAPT
NASDAQ Life Sciences

GSK to Acquire RAPT Therapeutics for $2.2 Billion, Offering $58.00 Per Share in Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
10
Price
$57.44
Mkt Cap
$972.652M
52W Low
$5.665
52W High
$42.392
52W Position info
914% above low
Off High info
at 52W high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

RAPT has more than doubled off its 52-week low of $5.665.

Summary

RAPT Therapeutics has entered a definitive agreement to be acquired by GSK for $58.00 per share in cash, valuing the company at an estimated $2.2 billion.


Key Events · M&A and Partnerships · RAPT

  • Acquisition Agreement Announced

    GSK plc has entered a definitive agreement to acquire RAPT Therapeutics, Inc. through a cash tender offer.

  • Offer Price and Valuation

    GSK will pay RAPT shareholders $58.00 per share in cash, totaling an estimated aggregate equity value of $2.2 billion.

  • Significant Premium

    The offer price of $58.00 per share represents a premium to the current stock price and is substantially above the company's 52-week high of $42.39.

  • Strategic Asset Acquired

    The acquisition includes ozureprubart, a long-acting anti-IgE monoclonal antibody in Phase IIb clinical development for prophylactic protection against food allergens.


Analysis · RAPT · Life Sciences

This filing announces a definitive agreement for GSK to acquire RAPT Therapeutics, representing a fundamental change in the company's future. The acquisition price of $58.00 per share in cash is a significant premium to the current stock price of $57.44 and substantially above the company's 52-week high of $42.39. This transaction provides immediate and substantial value to RAPT shareholders. The strategic rationale for GSK is to gain global rights to ozureprubart, a promising anti-IgE antibody in Phase IIb development for food allergies, which complements GSK's existing pipeline in respiratory, immunology, and inflammation. Investors should expect the stock price to converge with the offer price, assuming the deal closes as expected in Q1 2026.

At the time of this filing, RAPT was trading at $57.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $972.7M. The 52-week trading range was $5.67 to $42.39. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RAPT - Latest Insights

RAPT
Mar 03, 2026, 9:02 AM EST
Filing Type: 8-K
Importance Score:
10
Price at Filing: $58.00
Real-time Price: $58.00 info
Change: $0 (0%) info
Market Cap: $1.608B info
RAPT
Mar 03, 2026, 6:05 AM EST
Filing Type: SC 14D9/A
Importance Score:
10
Price at Filing: $58.00
Real-time Price: $58.00 info
Change: $0 (0%) info
Market Cap: $1.608B info
RAPT
Mar 03, 2026, 6:04 AM EST
Filing Type: SC TO-T/A
Importance Score:
10
Price at Filing: $58.00
Real-time Price: $58.00 info
Change: $0 (0%) info
Market Cap: $1.608B info
RAPT
Feb 24, 2026, 6:08 AM EST
Filing Type: SC TO-T/A
Importance Score:
8
Price at Filing: $57.98
Real-time Price: $58.00 info
Change: +$0.020 (+0.03%) info
Market Cap: $1.608B info
RAPT
Feb 24, 2026, 6:01 AM EST
Filing Type: SC 14D9/A
Importance Score:
8
Price at Filing: $57.98
Real-time Price: $58.00 info
Change: +$0.020 (+0.03%) info
Market Cap: $1.608B info